Core Viewpoint - FORVIA has successfully priced USD 500 million of senior notes due 2033, indicating a strong demand and diversification of its investor base [2][3]. Group 1: Financial Details - The senior notes have a principal amount of USD 500 million and an interest rate of 6.750% [2]. - The notes received credit ratings of "BB+" from Fitch Ratings, "B1" from Moody's, and "BB-" from Standard & Poor's [3]. - Proceeds from the notes will be used to repay existing long-term financial liabilities, aiming to extend the company's debt maturity [3]. Group 2: Market Response and Future Plans - The transaction was significantly oversubscribed, reflecting strong interest from investors [3]. - An application will be made to list the notes on the official list of Euronext Dublin, with settlement expected on September 23, 2025 [4].

Core Viewpoint - DaVita Inc. has announced an increase in its private offering of 6.750% senior notes due 2033 from $750 million to $1 billion, priced at 100% of face value with a 6.750% yield [1] Group 1: Offering Details - The offering of the 2033 notes is set to close on May 23, 2025, pending customary closing conditions [1] - The notes are being offered to qualified institutional buyers under Rule 144A and certain non-U.S. persons in compliance with Regulation S [3] Group 2: Use of Proceeds - DaVita plans to use the net proceeds from the offering to repay outstanding revolving credit facility borrowings, cover related interest, and pay associated costs [2] - Any remaining proceeds will be allocated for general corporate purposes, including stock repurchases, working capital, and capital expenditures [2] Group 3: Company Overview - DaVita is a healthcare provider focused on transforming care delivery to enhance the quality of life for patients globally, particularly in kidney care [5] - The company has been a leader in clinical quality and innovation for 25 years, providing care at all stages of kidney health [5]